# 503492587 09/23/2015

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3539212

SUBMISSION TYPE:		NEW ASSIC	NEW ASSIGNMENT		
IATURE OF CONVEYA	ASSIGNME	ASSIGNMENT			
CONVEYING PARTY D	ATA				
		Name			Execution Date
THE DOW CHEMICAL C	OMPAN	(			02/26/2007
RECEIVING PARTY DA	ТА				
Name:	DFB BI	DFB BIOTECH, INC.			
Street Address:	3909 HI	JLEN ST.			
City:	FORT V	/ORTH			
State/Country:	TEXAS				
Postal Code:	76107				
PROPERTY NUMBERS	Total: 1				
Property Type		Nu	Imber	7	
		4252215		_	
	I				
CORRESPONDENCE D					
. ,		617)646-8646			
Correspondence will build using a fax number, if					
Phone:		617-646-8000			
Email:	I	atents_YahuaC@	WolfGreenfield.con	ı	
• · · · ·	rrespondent Name: WOLF GREENFIELD				
Correspondent Name:					
Address Line 1:		00 ATLANTIC A			
•	(	00 ATLANTIC A			
Address Line 1:		00 ATLANTIC A	/ENUE ACHUSETTS 02210		
Address Line 1: Address Line 4:		00 ATLANTIC AN BOSTON, MASSA	VENUE ACHUSETTS 02210 00US04		
Address Line 1: Address Line 4: ATTORNEY DOCKET NU		00 ATLANTIC AN BOSTON, MASSA P0850.7000	/ENUE ACHUSETTS 02210 00US04 BRANDT		

#### ASSIGNMENT

WHEREAS, The Dow Chemical Company, (hereafter "TDCC"), a Delaware corporation having a place of business at 2030 Dow Center, Midland Michigan 486744, owns, by assignment, all right, title, and interest in the patents and patent applications listed in Appendix A, and any invention claimed therein; and

DFB Biotech, Inc. (hereafter "DFB"), a Delaware corporation with offices located at 3909 Hulen St., Fort Worth, Texas 76107, desires to own TDCC's entire right, title, and interest in and to the inventions, and in and to the patents and patent applications listed in Appendix A.

NOW THEREFORE, be it known that, for good and valuable consideration, receipt of which is hereby acknowledged, TDCC hereby sells, assigns, transfers, and sets over to DFB, its lawful successors and assigns, TDCC's entire right, title, and interest in and to the patent and patent applications listed in Appendix A, the invention claimed therein, and all Letters Patent that may be granted thereon in the United States or foreign countries, and all reissues, reexaminations, and extensions, and the like thereof; and all rights to claim priority on the basis of such applications; and TDCC hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to DFB Biotech, Inc., its successors and assigns, in accordance with the terms of this Assignment;

AND, TDCC HEREBY further covenants that TDCC has the full right to convey the interest assigned by this Assignment, TDCC will take all action and execute all documents necessary to perfect the interest assigned hereby, and TDCC has not executed and will not execute any agreement in conflict with this Assignment;

AND, TDCC HEREBY further covenants and agrees that TDCC, through its officers and employees, will, without further consideration, communicate with DFB, its successors and assigns, any facts known to TDCC and its officers and employees respecting the invention and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver all papers that may be necessary or desirable to perfect the title to the invention in said DFB, its successors and assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths, and generally do everything possible to aid DFB, its successors and assigns, to obtain and enforce proper patent protection for the invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by DFB, its successors and assigns.

IN TESTIMONY WHEREOF, each party has caused its authorized representative to execute this Assignment.

The Dow Chemical Company

By: Michod & Alaum Date: Fab 26, 2007

DFB Biotech, Inc.

Ву: \_// Date: MARCH 5 2007

## APPENDIX A

#### I. Seki & Fujiyama Patents

# A. Plant Cell Having Animal-Type Sugar chain Adding Function

Jurisdiction	App. No.	Publication No./Patent No.
PCT	PCT/JP02/02091	WO02070672
United States	10/467,101	2005/0144670A1
Mexico	03/008001	
Japan	2001-062704	20011333787A2
European Patent	02702772.1	EP1367881A2
China	2002/0805959	1541059
Canada	2438375	24338375
Brazil	0207857	
South Africa	2003/06111	
India		
Australia		

Any and all patents and patent applications claiming priority to JP2001-062704 not expressly listed above.

B. Method for Secretory Production of Glycoprotein having Human-Type Sugar Chain using Plant Cell

Jurisdiction	App. No.	Publication No./Patent No.
PCT	PCT/JP02/00361	WO02057468
United States	10/466,941	2004/0214273A1
Mexico	03/006426	
Japan	2001-12519	
Japan	2002-558520	2005505234T2
European Patent	02715831.0	EP1356068A2
China	2002/0804525	1549861
Canada	2434364	2434364
Brazil	0206546	
South Africa	2003/06406	
India		
Australia		

Any and all patents and patent applications claiming priority to JP2001-12519 not expressly listed above.

## PATENT REEL: 036636 FRAME: 0817

Jurisdiction	App. No.	Publication No./Patent No.
PCT	PCT/JP99/06881	WO00034490
United States	10/857,651	6,998,267
United States	10/870,635	2005/0143564
Mexico	01/005778	
Japan	10/350584	
Japan	2000-586923	2002543760T2
European Patent	99959703.2	EP1137789A1
Canada	2354377	2354377
Israel	143641	
Brazil	9917026	
South Africa	2001/04695	
Australia	16813/00	771908
New Zealand	512185	
Singapore	2001103375-2	
Argentina		
Chile		

Any and all patents and patent applications claiming priority to JP10/350584 not expressly listed above.

### II. Anderson et. Al.

Plant Production of Immunoglobulins with Reduced Fucosylation

Jurisdiction App. No.	Publication No./Patent No.
PCT PCT/US03/037905	WO04050838
United States 60/429,385	
United States 10/536,875	
Japan 2004-557359	2006517392T2
European Patent 63796484.8	EP1606385A2
Canada 2506744	2506744
Brazil 0316739	
Australia 3298727	
China	
Chile	
Argentina	

Any and all patents and patent applications claiming priority to US 60/429,385 not expressly listed above.

# PATENT REEL: 036636 FRAME: 0818

**RECORDED: 09/23/2015**